Main menu

Targeted adaptive sampling enables clinical pharmacogenomics testing and genome-wide genotyping


Over 90% of people carry variants that could impact drug efficacy or safety. Here, Peng and Lin et al. validated Oxford Nanopore sequencing for accurate, haplotype-resolved testing of 35 pharmacogenomic targets, achieving high accuracy and enabling genome-wide genotyping — a scalable, cost-effective step towards truly personalised medicine.

Watch Pamela Gan’s talk at London Calling 2025

Sample type: cell lines, human blood

Kit: ligation sequencing kit, native barcoding kit

Authors: Pamela Gan Hui Peng, Yeo Han Lin, Muhammad Irfan Bin Hajis, Yusuf Maulana, Audrey Ng Qi Hui, Kevin Nathanael Ramanto, Marta Nisita Dewanggana, Astrid Irwanto, Levana Sani, Ling Goh Liuh, Mar Gonzalez-Porta

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

纳米孔技术

订阅 Nanopore 更新 资源库及发表刊物 什么是 Nanopore 社区

关于 Oxford Nanopore

新闻 公司历程 可持续发展 领导团队 媒体资源和联系方式 投资者 合作者 在 Oxford Nanopore 工作 职位空缺 商业信息 BSI 27001 accreditationBSI 90001 accreditationBSI mark of trust
Chinese flag